Abbott Laboratories logo

ABT

Abbott Laboratories
NYSE
Healthcare
Medical Devices
abbott.com
$.
$1.63(+1.56%)
Market closedupdated just now
O: $106.15H: $106.85L: $104.60

Market Cap

$183.77B

P/E Ratio

39.48

52W High

$132.03

52W Low

$81.97

C

Quality Score

ABT scores 68/100 (C) — dividend safety is the strongest factor, momentum the weakest.

68

/ 100

See the full 7-factor breakdown with PRO.

Upgrade
More historical data is needed for full RSI, MACD, and Bollinger readings.

AI Technical Interpretation

PRO turns ABT's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.

Upgrade to PRO

AI “Why Did It Move?”

Get a ranked, evidence-grounded read on what's likely driving ABT's move today — news, earnings, analyst activity, sector context, and technicals combined.

Upgrade to PRO

Analyst Ratings
28 analysts

ConsensusBuy
Strong Buy5
Buy18
Hold5
Sell0
Strong Sell0
Avg price target+11.60%
$118.52from $106.20
Low $100.00Median $120.00High $130.00

Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.

AI Fair Value Estimate

Get an AI analyst's take on whether ABT looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.

Upgrade to PRO

AI Post-Earnings Recap

Reported 2026-09-30

Unlock the post-earnings recap for ABT

Get an AI analyst's read on how the report went and how the stock reacted.

Upgrade to PRO

Dividend
Quarterly

Forward yield

2.37%

Annual / share

$2.52

Last ex-date

Oct 15, 2026

Last payment

Nov 16, 2026

Recent payments

Ex-date Oct 15, 2026$0.63
Ex-date Jul 15, 2026$0.63
Ex-date Apr 15, 2026$0.63
Ex-date Jan 15, 2026$0.63
Ex-date Oct 15, 2025$0.59
Ex-date Jul 15, 2025$0.59
Ex-date Apr 15, 2025$0.59
Ex-date Jan 15, 2025$0.59

Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.

AI Dividend Safety

Get an AI read on whether ABT's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.

Upgrade to PRO

Insider Trading
50 recent filings

Buys

31

Sells

0

Reported value

$77.07M

50 shown
DateInsiderTypeSharesPriceValueOwned
Sep 30, 2026

ROMAN, MICHAEL F

Director

Buy381$98.83$37,654.23-
Sep 30, 2026

AHUJA, NITA

Director

Buy318$98.83$31,427.94-
Sep 30, 2026

CONROY, KEVIN T

Director

Buy318$98.83$31,427.94-
Sep 30, 2026

GONZALEZ, PATRICIA PAOLA

Director

Buy333$98.83$32,910.39-
Sep 30, 2026

STRATTON, JOHN G

Director

Buy397$98.83$39,235.51-
Sep 23, 2026

CONROY, KEVIN T

Director

Other52,507$103.99$5.46M-
Sep 2, 2026

MCCOY, JOHN A. JR.

VICE PRESIDENT AND CONTROLLER

Other27$109.54$2,957.58-
Sep 1, 2026

BOUDREAU, PHILIP P

EVP AND CFO

Other388$110.36$42,819.68-
Sep 1, 2026

MCCOY, JOHN A. JR.

VICE PRESIDENT AND CONTROLLER

Other52$110.36$5,738.72-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other151,869$44.40$6.74M-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other218,535$115.57$25.26M-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other180,297$116.19$20.95M-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other151,869$0.00$0.00-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other246,963$0.00$0.00-
Aug 25, 2026

FORD, ROBERT B

Director, CHAIRMAN AND CEO

Other246,963$59.94$14.80M-
Aug 12, 2026

MORRONE, LOUIS H.

EXECUTIVE VICE PRESIDENT

Other12$107.99$1,295.88-
Aug 11, 2026

MORRONE, LOUIS H.

EXECUTIVE VICE PRESIDENT

Other5,850$109.83$642,505.50-
Jun 30, 2026

AHUJA, NITA

Director

Buy347$90.74$31,486.78-
Jun 30, 2026

CONROY, KEVIN T

Director

Buy231$90.74$20,960.94-
Jun 30, 2026

MORRONE, LOUIS H.

EXECUTIVE VICE PRESIDENT

Other269$92.71$24,938.99-
Jun 30, 2026

ROMAN, MICHAEL F

Director

Buy416$90.74$37,747.84-
Jun 30, 2026

GONZALEZ, PATRICIA PAOLA

Director

Buy363$90.74$32,938.62-
Jun 30, 2026

STRATTON, JOHN G

Director

Buy432$90.74$39,199.68-
Jun 27, 2026

CUSHMAN, ELIZABETH C.

EVP, GC AND SECRETARY

Other560$94.12$52,707.20-
May 7, 2026

STRATTON, JOHN G

Director

Other2,000$86.82$173,640.00-
Apr 28, 2026

MORELAND, MARY K

EXECUTIVE VICE PRESIDENT

Other5,314$94.41$501,694.74-
Apr 27, 2026

STARKS, DANIEL J

Director

Other10,000$92.65$926,537.00-
Apr 24, 2026

BLOUNT, SALLY E.

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

KUMBIER, MICHELLE

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

MCKINSTRY, NANCY

Director

Buy2,305$0.00$0.00-
Apr 24, 2026

MCKINSTRY, NANCY

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

O'GRADY, MICHAEL

Director

Buy5,929$0.00$0.00-
Apr 24, 2026

O'GRADY, MICHAEL

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

ROMAN, MICHAEL F

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

STARKS, DANIEL J

Director

Buy7,105$0.00$0.00-
Apr 24, 2026

STARKS, DANIEL J

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

AHUJA, NITA

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

BABINEAUX-FONTENOT, CLAIRE

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

CONROY, KEVIN T

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

GONZALEZ, PATRICIA PAOLA

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

MCDEW, DARREN W

Director

Buy2,286$0.00$0.00-
Apr 24, 2026

STRATTON, JOHN G

Director

Buy2,286$0.00$0.00-
Apr 23, 2026

BOUDREAU, PHILIP P

EVP AND CFO

Other8,909$92.04$819,984.36-
Apr 23, 2026

BOUDREAU, PHILIP P

EVP AND CFO

Other2,200$91.50$201,300.00-
Mar 31, 2026

ROMAN, MICHAEL F

Director

Buy367$102.67$37,679.89-
Mar 31, 2026

STRATTON, JOHN G

Director

Buy382$102.67$39,219.94-
Mar 31, 2026

ALPERN, ROBERT J

Director

Buy76$102.67$7,802.92-
Mar 31, 2026

GONZALEZ, PATRICIA PAOLA

Director

Buy321$102.67$32,957.07-
Mar 31, 2026

AHUJA, NITA

Director

Buy102$102.67$10,472.34-
Mar 23, 2026

ORVILLE, JACOB A

Senior Vice President

Buy13,255$0.00$0.00-

Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.

AI Stock Analysis

Unlock an in-depth, balanced bull/bear breakdown of ABT — catalysts, risks, and a plain-language read on the fundamentals.

Upgrade to PRO

Investor Copilot Notebook

Keep a thesis on ABT

Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.

Upgrade to PRO

Investment Thesis Timeline

See ABT's full timeline

Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.

Upgrade to PRO
TradingView
Sponsored

Deeper technical charting, indicators, and pattern tools that complement XMarketPro's research.

Open advanced charts

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

TrendSpider
Sponsored

Automated technical analysis, charting, and pattern recognition for active traders.

Explore automated technical analysis

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Seeking Alpha
Sponsored

Another independent research perspective to compare against XMarketPro's own analysis.

Compare with additional research

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Interactive Brokers
Sponsored

A well-established U.S. brokerage for investors moving from research into execution.

Explore brokerage options

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

ABT logo
About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Visit abbott.com

Key Statistics

Open
$106.15
Prev Close
$104.57
Day High
$106.85
Day Low
$104.60
Volume
8.44M
Market Cap
$183.77B
P/E Ratio
39.48
EPS
$2.69
Beta
0.58
Dividend Yield
+2.41%
52W High
$132.03
52W Low
$81.97
Analyst Target
—